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INTRODUCTION
Solitary extramedually plasmacytomas represent approxi-
mately 3% of all plasma cell neoplasms (1). They most com-
monly affect men in their elderly 60s and occur in the up-
per respiratory tract (paranasal sinuses, nose, nasopharynx,
and tonsils). They also occur in lymph nodes, lung, thyroid,
gastrointestinal tract, liver, spleen, pancreas, testes, breast,
or skin (2). Although extramedually plasmacytomas are not
common in newly diagnosed multiple myeloma, classic mye-
loma must be excluded by thorough staging. A monoclonal
protein is detected in the serum and urine in approximately
25% of patients (3-8). A monoclonal protein in the serum
and urine, lytic bone lesions, anemia, renal insufficiency, and
hypercalcemia should be excluded. It is most unusual for this
condition to present in the liver as a primary solitary lesion.
Only a few cases of primary hepatic extramedually plasmcy-
toma have been reported; however, these cases revealed mon-
oclonal gammopathy in the serum and/or urine (9-12). Here
we present the first case of truly localized solitary hepatic
extramedually plasmacytoma without evidence of myeloma
elsewhere. 
CASE REPORT
A 63-yr-old man was referred from a primary clinic due
to a hepatic mass on ultrasonography. He had well-controlled
hypertension and diabetes. Physical examination was unre-
markable. Computed tomography (CT) scans (Sensation 4,
Siemens Medical System, Forchheim, Germany) were ob-
tained after injection of 150 mL of ionic contrast material
(Iopamiro 300; Bracco, Milano, Italy). Contrast-enhanced
CT of the liver was performed with 2.5 mm detector colli-
mation, 5 mm slice thickness, 15 mm table feed, 6 pitch, 1.5
mm reconstruction during the arterial phase (10 sec after 100
HU aortic enhancement) and portal venous phase (72 sec after
contrast injection). The arterial phase images showed a 2×2
cm-sized well enhanced mass in segment VI of the liver. This
mass showed hypodensity on the portal venous phase (Fig.
1A, B). Liver magnetic resonance imaging (MRI) revealed a
well-defined mass in Segment VI. This mass showed low sig-
nal intensity on T1-weighted image and high signal inten-
sity on T2-weighted image (Fig. 1C, D). Initial impression
of the contrast-enhanced CT suggested the possibility of hy-
pervascular hepatic tumors including adenoma, focal nodu-
lar hyperplasia, and hepatocellular carcinoma. Hematologi-
cal indexes, liver function test, and renal functions were within
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Solitary Extramedullary Plasmacytoma of the Liver without Systemic
Monoclonal Gammopathy 
Extramedullary plasmacytoma of the liver is a very rare tumor. Although a few cases
of extramedullary plasmacytoma of the liver have been reported, we could not find
any report on truly localized extramedullary plasmacytoma of the liver in the litera-
ture. The patient was a 63-yr-old man who exhibited a solitary liver mass on dyna-
mic computed tomography and magnetic resonance imaging. Histologically, the
tumor was composed of mature plasma cells with mild atypia. Immunohistochem-
istry demonstrated monoclonal IgG and Kappa light chain expression. Bone mar-
row examination revealed no abnormalities. There was no evidence of a mono-
clonal protein in the serum and urine, lytic bone lesions, anemia, renal insufficien-
cy, and hypercalcemia. The patient was treated with 5,000 cGy of radiotherapy,
and the tumor disappeared 6 months after treatment. 
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the normal limits. The patient was negative for viral markers,
and  -fetoprotein was not increased. A needle biopsy of the
liver mass and bone marrow trephine biopsies were performed.
The histological examination of the liver biopsy disclosed
diffuse solid proliferation of monotonous small round to ovoid
cells without any lymphoid cells, eosinophils, or fibroblasts.
They had eccentric cytoplasm and round nuclei with periph-
eral condensation of chromatin. Occasional binucleated forms
were noted. The diagnosis after immunohistochemical stain-
ing was plasmacytoma with IgG and kappa type (Fig. 2). The
bone marrow biopsy specimens showed 30% marrow cellu-
larity but were otherwise normal. Serum calcium,  -2 mic-
roglobulin, and serum and urine protein immunoelectro-
phoresis were normal. Skeletal radiography revealed no ab-
normalities. The patient was treated with 5,000 cGy of radio-
therapy. Follow-up contrast-enhanced CT after six month
showed treatment response of the hepatic mass (Fig. 3). 
DISCUSSION
Most patients with plasma cell neoplasia have generalized
disease at diagnosis, i.e. multiple myeloma (3). Solitary ext-
ramedullary plasmacytoma represents approximately 3% of
all plasma cell neoplasm (4, 5). Although solitary extrame-
dullary plasmacytoma can arise throughout the body, almost
90% arise in the head and neck, especially in the upper res-
piratory tract including the nasal cavity, sinuses, oropharynx,
salivary glands, and larynx (2, 6, 13-15). The second most
frequent site is the gastro intestinal tract. A variety of other
sites can rarely be involved, including testis, bladder, urethra,
breast, ovary, pleura, thyroid, orbit, brain, and skin (1). 
The diagnosis of solitary extramedullary plasmacytoma
requires the demonstration of a monoclonal plasma cell infil-
trate without any evidence of multiple myeloma elsewhere
(5). The patient described here is a man who presented with
a solitary hepatic extramedually plasmacytoma without evi-
dence of myeloma elsewhere including no monoclonal pro-
tein in the serum or urine. Only a few cases of primary hep-
atic extramedually plasamcytoma have been reported; how-
ever, these cases revealed monoclonal gammopathy in the
serum and/or urine (9-12). Brinch et al. (6) reported only 3
out of 18 patients with extramedullary plasmacytoma had a
systemic M-protein; however, the presenting sites of extra-
Fig. 1. On contrast-enhanced computed tomography, the arterial phase image (A) shows a 2×2 cm-sized well enhanced mass in seg-
ment VI of the liver. This mass shows hypodensity on the portal venous phase (B). On magnetic resomance imaging, the T1-weighted
image (C) shows a low signal intensity mass in segment VI. This mass shows high signal intensity in a T2-weighted image (D).
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medullary plasmacytomas included in the report were the
upper respiratory tract (epipharynx, nose, paranasal sinuses,
and thorax). This is the first report of truly localized solitary
hepatic extramedually plasmacytoma without evidence of
monoclonal gammopathy in the serum and urine. The rea-
son for the diverse incidence of systemic monoclonal gam-
mopathy between the presenting sites is not documented
but could be related with the time at the diagnosis of the
plasmacytomas. The predictive value of the presence or ab-
sence of an M-component for the later development of mye-
lomatosis was poor (6).
The current treatment of choice is radiotherapy because
these tumors are highly radiosensitive. A radiation dose of
4,000 to 5,000 cGy over 4 to 5 weeks was associated with a
less than 5% risk of local recurrence (7). No local recurrences
were observed with radiation doses of at least 4,500 cGy (5).
In our patient, the plasmacytoma was located on the tip of
the right lobe, and the patient was treated with 5,000 cGy
of radiotherapy encompassing the primary tumor with an
ample margin. For extramedually plasmacytomas at sites
other than head and neck, complete surgical removal should
be considered if feasible (3). The diagnosis of patients with
Fig. 2. The liver shows diffuse solid proliferation of monotonous small round to ovoid cells (A: H&E, ×100). They have eccentric cytoplasm
and round nuclei with peripheral condensation of chromatin (B: H&E, ×400). Immunohistochemical stains of the hepatic mass exhibit mono-
clonality for IgG heavy chain (C: ABC, ×200) and kappa light chain (D: ABC, ×200).
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extramedually plasmacytomas is usually made after surgical
excision (9, 10). It is recommended that patients with posi-
tive surgical margins should receive adjuvant radiotherapy,
but adjuvant radiotherapy is not recommended for patients
who have undergone complete surgical excision with a neg-
ative margin (3). There is no evidence that adjuvant chemo-
therapy improves patients’ outcome (5). As a result, extra-
medullary plasmacytoma has a relatively favorable progno-
sis, and a solitary extramedullaty plasmacytoma can be a
curable disease by meticulous staging. At least 70% of these
patients remain disease-free at 10 yr, and fewer than 30%
develop a distant failure in the form of multiple myeloma
or multiple extramedulary tumors (2, 4-8). 
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Fig. 3. Follow-up contrast-enhanced CT after six months shows
treatment response of the hepatic mass.